Effects of sitagliptin beyond glycemic control: focus on quality of life

Conclusions:
These results suggest that the actions of DPP-4 inhibitors improve not only glycemic control, but also blood pressure, lipid profiles, and quality of life (QOL). Sitagliptin is a sound agent for use in the comprehensive treatment of patients with T2DM.

Source: Cardiovascular Diabetology - February 21, 2013 Category: Cardiology Authors: Yoshiko SakamotoJun-ichi OyamaHideo IkedaShigetaka KurokiShigeki GondohTaketo IwamotoYasufumi UchidaKazuhisa KodamaAtsushi HiwatashiMitsuhiro ShimomuraIsao TaguchiTeruo InoueKoichi Node Source Type: research